Pasithea Therapeutics Corp
KTTA1.130USD
-0.390-25.66%
Close 05/07, 16:00（ET）Quotes delayed by 15 min
1.58MMarket Cap
LossP/E TTM
More Details of Pasithea Therapeutics Corp Company
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Company Info
Company codeKTTA
Company namePasithea Therapeutics Corp
IPO dateAug 13, 2021
Founded at2020
CEODr. Tiago Reis Marques
Number of employees4
Security typeOrdinary Share
Fiscal year-endAug 13
Address1111 Lincoln Road, Suite 500
CityMIAMI BEACH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33139
Phone17025144174
Websitehttps://www.pasithea.com/
Company codeKTTA
IPO dateAug 13, 2021
Founded at2020
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Executive Chairman, Co-Founder
Executive Chairman, Co-Founder
66.36K
--
Dr. Tiago Reis Marques
Dr. Tiago Reis Marques
Chief Executive Officer, Director
Chief Executive Officer, Director
40.50K
+4.30%
Mr. Alfred J. Novak
Mr. Alfred J. Novak
Independent Director
Independent Director
3.50K
--
Mr. Simon Dumesnil
Mr. Simon Dumesnil
Independent Director
Independent Director
2.50K
--
Mr. Daniel H. Schneiderman
Mr. Daniel H. Schneiderman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Graeme Currie, Ph.D.
Dr. Graeme Currie, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Emer Leahy, Ph.D.
Dr. Emer Leahy, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lisa Carlton-wilson
Ms. Lisa Carlton-wilson
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Executive Chairman, Co-Founder
Executive Chairman, Co-Founder
66.36K
--
Dr. Tiago Reis Marques
Dr. Tiago Reis Marques
Chief Executive Officer, Director
Chief Executive Officer, Director
40.50K
+4.30%
Mr. Alfred J. Novak
Mr. Alfred J. Novak
Independent Director
Independent Director
3.50K
--
Mr. Simon Dumesnil
Mr. Simon Dumesnil
Independent Director
Independent Director
2.50K
--
Mr. Daniel H. Schneiderman
Mr. Daniel H. Schneiderman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Graeme Currie, Ph.D.
Dr. Graeme Currie, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, Mar 28
Update time: Fri, Mar 28
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
PD Joint Holdings, LLC
4.82%
Steinman (Lawrence)
2.45%
Armistice Capital LLC
2.25%
AdvisorShares Investments, LLC
1.98%
Marques (Tiago Reis)
1.50%
Other
86.99%
Shareholder Statistics
Shareholder
Proportion
PD Joint Holdings, LLC
4.82%
Steinman (Lawrence)
2.45%
Armistice Capital LLC
2.25%
AdvisorShares Investments, LLC
1.98%
Marques (Tiago Reis)
1.50%
Other
86.99%
Type
Shareholder
Proportion
Corporation
4.82%
Individual Investor
4.17%
Investment Advisor
2.50%
Hedge Fund
2.32%
Investment Advisor/Hedge Fund
0.32%
Other
85.86%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
30
382.77K
14.15%
-456.80K
2024Q4
30
322.63K
25.48%
-746.50K
2024Q3
36
1.59M
35.25%
-4.18M
2024Q2
34
1.50M
26.15%
-4.28M
2024Q1
35
1.50M
29.85%
-8.78M
2023Q4
34
6.19M
23.97%
-3.95M
2023Q3
36
7.48M
28.68%
-4.88M
2023Q2
34
7.60M
28.90%
-4.79M
2023Q1
33
7.58M
28.81%
-4.78M
2022Q4
31
11.02M
39.56%
-1.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PD Joint Holdings, LLC
130.43K
4.82%
--
--
Apr 29, 2024
Steinman (Lawrence)
66.36K
2.45%
--
--
Mar 01, 2025
Armistice Capital LLC
61.00K
2.25%
-54.88K
-47.36%
Dec 31, 2024
AdvisorShares Investments, LLC
48.55K
1.79%
+48.55K
--
Feb 28, 2025
Marques (Tiago Reis)
38.83K
1.44%
+833.00
+2.19%
Apr 29, 2024
UBS Financial Services, Inc.
12.87K
0.48%
+6.30K
+95.95%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.84K
0.14%
--
--
Feb 28, 2025
Novak (Alfred J)
3.50K
0.13%
+3.50K
--
Jun 13, 2024
Dumesnil (Simon)
2.50K
0.09%
--
--
Apr 29, 2024
Tower Research Capital LLC
1.89K
0.07%
+1.28K
+213.81%
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
AdvisorShares Psychedelics ETF
0.84%
AdvisorShares Psychedelics ETF
Proportion0.84%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Date
Type
Ratio
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1
Dec 28, 2023
Merger
20<1